<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969553</url>
  </required_header>
  <id_info>
    <org_study_id>1230.16</org_study_id>
    <nct_id>NCT00969553</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers</brief_title>
  <official_title>A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI
      6727 in Asian cancer patients, and to provide safety data in terms of drug-related adverse
      events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>3 weeks after last administration of BI 6727</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>about 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>about 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response</measure>
    <time_frame>Every other course from entry to end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>Selected time points during first 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 6727</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schedule A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 6727</intervention_name>
    <description>Dose level 1</description>
    <arm_group_label>BI 6727</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with histologically or cytologically confirmed diagnosis of advanced solid
             cancer

          2. Age 18 years or older

          3. Written informed consent

          4. Eastern Cooperative Oncology Group (ECOG) performance score 2 or less

        Exclusion criteria:

          1. Serious illness or concomitant non-oncological disease.

          2. Pregnancy or breast feeding

          3. Active infectious disease

          4. Absolute neutrophil count less than 1,500/cubic millimeter

          5. Platelet count less than 100,000/cubic millimeter

          6. Bilirubin greater than 1.5 mg/dL (&gt; 26 Âµmol/L, SI unit equivalent)

          7. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than 2.5 times the upper limit of normal

          8. Serum creatinine greater than 1.5x ULN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.16.886002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.16.886001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>October 23, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

